Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

EA Pharma to co-promote Humira in Japan with AbbVie GK

Executive Summary

Eisai Co. Ltd.'s subsidiary EA Pharma Co. Ltd. received rights to co-promote in Japan AbbVie Inc.'s (through its Japanese subsidiary AbbVie GK) fully human anti-TNF-a monoclonal antibody Humira (adalimumab) for gastrointestinal disease indications including ulcerative colitis, Crohn’s disease, and intestinal Behçet’s disease.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Marketing (Licensing)

Related Companies